Currently, nine clinical trials are on the list (two of them in India), where Aviptadil is being tried via both the inhalational and intravenous route and tested subsequently based on some outcome parameters to assess the safety and efficacy of the drug in comparison to the use of placebo/Remdesivir/Monoclonal antibody and other immunosuppressants in treatment of COVID 19 disease complicated with severe respiratory failure. The details of those trials are summarized in [Table 2]. Among those 9 trials, 7 of them are in the recruitment stage comprising the trial with maximum sample size, where one trial is completed and the data of the remaining one has been made available recently.{Table 2}
Market Data 
Markets 
AI
